Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival-Reference-Cited by-同舟云学术

Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival

Published:2024-02 Issue:2 Volume:48 Page:102282
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Mejait Amel,Roux Charles,Soret Marine,Larrey Edouard,Wagner Mathilde,Bijot Jean Charles,Lussey-Lepoutre Charlotte,Thabut Dominique,Goumard Claire,Maksud Philippe,Allaire Manon

Publisher

Elsevier BV

Reference11 articles.

1. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial;Vilgrain;Lancet Oncol,2017

2. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma;Chow;J Clin Oncol,2018

3. Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages;Moctezuma-Velazquez;Dig Dis Sci,2021

4. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC;Guiu;Cardiovasc Intervent Radiol,2022

5. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial;Garin;Lancet Gastroenterol Hepatol,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The current status and future of targeted-immune combination for hepatocellular carcinoma;Frontiers in Immunology;2024-08-05

2. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?;Current Oncology;2024-05-31